71 results on '"Lacouture, Mario E."'
Search Results
2. First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial
3. Dermatologic immune-related adverse events to checkpoint inhibitors in cancer
4. Dermatologist awareness of scalp cooling for chemotherapy-induced alopecia
5. A multidisciplinary approach to optimizing care of patients treated with alpelisib
6. Shared decision making for patients with breast and gynecologic malignancies undergoing chemotherapy associated with persistent alopecia
7. Quality of life before and after treatment of cutaneous metastases with palliative radiotherapy
8. 33655 Noninvasive, in vivo, characterization of cutaneous metastases using a novel multimodal RCM-OCT imaging device: A case-series
9. Effect of immune checkpoint inhibitors on asthma
10. Ibrutinib-associated dermatologic toxicities: A systematic review and meta-analysis
11. Noninvasive Genomic Characterization of Patients with Nonsclerotic and Superficially Sclerotic Chronic Cutaneous Graft-Versus-Host Disease Identified a Novel Gene Signature in Responders to Ruxolitinib Cream
12. Interim Results of a Pilot, Prospective, Randomized, Double-Blinded, Vehicle-Controlled Trial on Safety and Efficacy of a Topical Inhibitor of Janus Kinase 1/2 (Ruxolitinib INCB018424 Phosphate 1.5% Cream) for Non-Sclerotic and Superficially Sclerotic Chronic Cutaneous Graft-Versus-Host Disease
13. Dermatologic infections in cancer patients treated with checkpoint inhibitors
14. Corrigendum to ‘SJS/TEN 2019: From science to translation’ [J. Dermatol. Sci. 98/1 (2020) 2–12]
15. Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events
16. Restorative oncodermatology: Diagnosis and management of dermatologic sequelae from cancer therapies
17. 27891 Safety and efficacy of an Avena sativa (oat) skin care regimen for therapy-related xerosis and pruritus in adult oncology patients undergoing systemic cancer treatments
18. Immune-related cutaneous adverse events due to checkpoint inhibitors
19. Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy
20. Incidence of dermatologic adverse events in patients with cancer treated with concurrent immune checkpoint inhibitors and radiation therapy: A systematic review and meta-analysis
21. Association of interleukin-6 and tumor necrosis factor-α with mortality in hospitalized patients with cancer
22. Immune checkpoint inhibitors to treat cutaneous malignancies
23. Immune checkpoint inhibitor–related dermatologic adverse events
24. Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features
25. Bullous disorders associated with PD-1 and PD-L1 inhibitors: Pharmacovigilance analysis of the United States Food and Drug Administration Adverse Event Reporting System from the Research on Adverse Drug Events And Reports Program
26. Vulvar lichen sclerosus in the setting of cancer treatment – A case series and review of the literature
27. SJS/TEN 2019: From science to translation
28. Vitiligo Following Autologous Hematopoietic Stem Cell Transplantation
29. Randomized controlled trial of cryotherapy to prevent paclitaxel-induced peripheral neuropathy (RU221511I); an ACCRU trial
30. Drugs as a Frequent Cause of Acute Rash in Patients after CD34+-Selected Peripheral Blood Stem Cell Transplantation
31. Incidence and risk of developing photosensitivity with targeted anticancer therapies
32. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study
33. Hair disorders in cancer survivors
34. Hair disorders in patients with cancer
35. Markers of systemic involvement and death in hospitalized cancer patients with severe cutaneous adverse reactions
36. Regorafenib Dose-Optimization Study (ReDOS): A Phase 2 Randomized Study to Evaluate Dosing Strategies for Regorafenib in Patients with Refractory Metastatic Colorectal Cancer - An ACCRU Network Study
37. Li-Fraumeni Syndrome-related Malignancies Involving the Genitourinary Tract: Review of a Single-institution Experience
38. Pruritus Associated with Targeted Anticancer Therapies and Their Management
39. Inflammatory dermatoses, infections, and drug eruptions are the most common skin conditions in hospitalized cancer patients
40. Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review
41. The microbial flora of taxane therapy–associated nail disease in cancer patients
42. SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation
43. Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis
44. A prospective, randomized, double-blinded, split-face/chest study of prophylactic topical dapsone 5% gel versus moisturizer for the prevention of cetuximab-induced acneiform rash
45. Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042)
46. A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer
47. Reply to: “Skin moisturization for xerosis related to targeted anticancer therapies”
48. Incidence and risk of xerosis with targeted anticancer therapies
49. Current Practices in the Management of Adverse Events Associated With Targeted Therapies for Advanced Renal Cell Carcinoma: A National Survey of Oncologists
50. Ipilimumab in patients with cancer and the management of dermatologic adverse events
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.